ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:

Dictionar de medicamente online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dictionar medical online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Puteti trimite articole cu tema medicala la
adresa de email

Solutie antistress!
Construieste poduri :)
Joc, Construieste podul, Cargo Bridge

Prinde pisica neagra :)
Prinde pisica neagra- Chat Noir - Flash game

Statement On IMPROVE-IT Study

The academic leadership of the IMPROVE-IT trial recommended increasing the size of the patient population up to 18,000. Merck/Schering-Plough Pharmaceuticals, sponsor of the study, agreed with the recommendation. With the increase in enrollment, the current estimate for the completion of the trial is 2012. However, the actual date of completion is highly dependent on the observed event rates during the follow-up phase of the trial and the rate of enrollment. Therefore, it is not possible to determine with precision an exact date that the trial will end.

The recommendation from the academic leadership was based on recent analyses of the blinded, aggregate event rates in the IMPROVE-IT trial and published data on the relationship between lowering LDL cholesterol and clinical benefit that have emerged since the original protocol was prepared. This recommendation was not based on any factors related to the mechanism of action for ezetimibe.

The IMPROVE-IT trial is an event-driven cardiovascular clinical outcomes study. The purpose of the trial is to determine whether VYTORIN (ezetimibe/simvastatin) 10/40 mg provides incremental reductions in cardiovascular events in patients recovering from acute coronary syndrome in comparison to simvastatin 40 mg alone. The trial is also designed to determine whether this benefit can be seen in patients whose LDL cholesterol levels have been reduced to a lower absolute LDL cholesterol range than has been achieved in previous major outcomes studies.

Merck Forward-Looking Statement

This statement contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this statement should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2007, and in any risk factors or cautionary statements contained in the Company's periodic reports on Form 10-Q or current reports on Form 8-K, which the Company incorporates by reference.

VYTORIN® is a trademark of MSP Singapore Company, LLC. All other brands are trademarks of their respective owners and are not trademarks of MSP Singapore Company, LLC.

Merck
http://www.merck.com





Declaraþie cu privire la îmbunãtãþiri IT Studiul - Statement On IMPROVE-IT Study - articole medicale engleza - startsanatate